1-Benzyl-4-isocyanato-piperidine | 118546-43-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 1-Benzyl-4-isocyanato-piperidine
• 英文别名: 1-Benzyl-4-isocyanatopiperidine
• CAS: 118546-43-3
• 化学式: C₁₃H₁₆N₂O
• 分子量: 216.283
• InChiKey: YNSACCNXRKHNKC-UHFFFAOYSA-N

物化性质

• 沸点：
  306.5±35.0 °C(Predicted)
• 密度：
  1.09±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  2-氨基吡啶 、 1-Benzyl-4-isocyanato-piperidine 以 四氢呋喃 为溶剂， 反应 18.0h， 生成 1-(1-Benzyl-piperidin-4-yl)-3-pyridin-2-yl-urea
  参考文献：
  名称：

  1-(3-Cyanobenzylpiperidin-4-yl)-5-methyl-4-phenyl-1,3-dihydroimidazol-2-one:  A Selective High-Affinity Antagonist for the Human Dopamine D₄ Receptor with Excellent Selectivity over Ion Channels

  摘要：

  After the requirement of pseudocycle formation in the ureas 3 and 7 for hD(4) binding and selectivity was confirmed, structural hybridization with the known hD(4) ligand 2 led to the design and identification of the lead 4-(2-oxo-1,3-dihydroimidazol-2-yl)piperidine . Optimization studies were carried out on 8 with the aim of achieving 1000-fold selectivity for hD(4) over all other receptors while retaining the good pharmacokinetic properties of the lead. After initial preparation of 8 as a minor component in a low-yielding reaction, a novel and regioselective "four-step/one-pot'' procedure was developed which proved to be applicable to rapid investigation of the SAR of the 1,3-dihydroimidazol-2-one ring. Various changes to substituents attached to the 3-, 4-, or B-position of the 1,3-dihydroimidazol-2-one core of 8 did not significantly improve selectivity for hD(4) over hD(2) and hD(3). Greater Selectivity( > 1000-foId) was ultimately achieved by meta substitution of the benzyl group of 8 with various substituents. Compounds 28, 31, and 32 all possess the required selectivity for hD(4) over the other dopamine subtypes, but only 32 has > 1000-fold selectivity over-all the key counterscreens we tested against. Compound 32 is an antagonist at hD(4) and has a good pharmacokinetic profile in the rat, with excellent estimated in vivo receptor occupancy, thus making it a potentially useful pharmacological tool to investigate the role of the D-4 receptor.

  DOI：

  10.1021/jm991029k
• 作为产物：
  描述：

  4-氨基-1-苄基哌啶 在 tetrabutoxytitanium 、 N,N-二乙基-1,1,2,3,3,3-六氟丙胺 作用下， 以 二氯甲烷 为溶剂， 反应 0.5h， 生成 1-Benzyl-4-isocyanato-piperidine
  参考文献：
  名称：

  丙酮酸甲酯肟作为羰基合成子：脲、氨基甲酸酯、硫代氨基甲酸酯和苯胺的合成

  摘要：

  以丙酮酸甲酯肟为羰基合成子，开发了合成不对称脲、氨基甲酸酯、硫代氨基甲酸酯和苯胺的新策略。该试剂的固有反应性使得能够进行连续的取代，包括直接酰胺化和用各种亲核试剂进行一锅脱肟取代。该方法的实用性通过生物活性分子的合成得到了证明。

  DOI：

  10.1021/acs.orglett.4c01007

文献信息

• [EN] GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS<br/>[FR] DÉRIVÉS DE GALACTOPYRANOSYLE UTILES EN TANT QUE MÉDICAMENTS
  申请人：UNIV GENT

  公开号：WO2014001204A1

  公开（公告）日：2014-01-03

  This invention relates to carbamate-containing or thiocarbamate-containing galacto-pyranosyl compounds useful as therapeutic agents and being represented by the structural formula (II), wherein: X is O or S, R is selected from the group consisting of C1-8 alkyl, C3-10 cycloalkyl, aryl-C1-4 alkyl, heterocyclyl-C1-4 alkyl, cycloalkyl-C1-4 alkyl, aryl and heterocyclyl, wherein R is optionally substituted with one or more R9; R2, R3, R4, R6 and R7 are independently selected from the group consisting of hydroxyl and protected hydroxyl groups; R5 is selected from the group consisting C6-30 alkyl and arylalkyl; R8 is C6-30 alkyl; and each R9 is independently selected from the group consisting of halogen, hydroxy, trifluoromethyl, trifluoromethoxy, C1-8 alkoxy, C1-6 alkyl, cyano, methylthio, phenyl, phenoxy, chloromethyl, dichloromethyl, chloro-difluoromethyl, acetyl, nitro, benzyl, heterocyclyl and di-C1-4 alkyl-amino, or a pharmaceutically acceptable salt thereof.

  这项发明涉及含有碳酸酯或硫代碳酸酯的半乳糖基化合物，可作为治疗剂，并由结构式（II）表示，其中：X为O或S，R从以下组中选择：C1-8烷基、C3-10环烷基、芳基-C1-4烷基、杂环基-C1-4烷基、环烷基-C1-4烷基、芳基和杂环基，其中R可选择性地被一个或多个R9取代；R2、R3、R4、R6和R7独立地选自羟基和保护羟基基团；R5选自C6-30烷基和芳基烷基；R8为C6-30烷基；每个R9独立地选自卤素、羟基、三氟甲基、三氟甲氧基、C1-8烷氧基、C1-6烷基、氰基、甲硫基、苯基、苯氧基、氯甲基、二氯甲基、氯二氟甲基、乙酰基、硝基、苄基、杂环基和二C1-4烷基氨基，或其药用可接受盐。
• Inhibitors of serine proteases
  申请人：Cottrell M. Kevin

  公开号：US20070179167A1

  公开（公告）日：2007-08-02

  The present invention relates to compounds of formula I: or a pharmaceutically acceptable salt or mixtures thereof that inhibit serine protease activity, particularly the activity of hepatitis C virus NS3-NS4A protease.

  本发明涉及式I的化合物：或其药物可接受的盐或混合物，其抑制丝氨酸蛋白酶活性，特别是乙型肝炎病毒NS3-NS4A蛋白酶的活性。
• Optimisation of ITK inhibitors through successive iterative design cycles
  作者：Matthias Herdemann、Alexander Weber、Jérôme Jonveaux、Frank Schwoebel、Michael Stoeck、Isabelle Heit

  DOI：10.1016/j.bmcl.2011.01.035

  日期：2011.3

  Based on a hit cluster of compounds inhibiting interleukin-2 inducible T-cell kinase (ITK) in the submicromolar range a series of ITK inhibitor libraries were synthesized. Through iterative design cycles including kinase crystal structure information, indolylindazole libraries were identified which showed low nanomolar activity in enzymatic and cellular assays. The potential of these novel lead series was confirmed through in vivo tests in an anti-CD3-IL2 mouse model. The intravenous administration of highly potent ITK inhibitor 11o resulted in dose-dependent, efficient suppression of IL-2. (C) 2011 Elsevier Ltd. All rights reserved.
• GALACTOPYRANOSYL DERIVATIVES USEFUL AS MEDICAMENTS
  申请人：Universiteit van Gent

  公开号：EP2877480A1

  公开（公告）日：2015-06-03
• US9321796B2
  申请人：——

  公开号：US9321796B2

  公开（公告）日：2016-04-26